# Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Variegate Porphyria (VP)

> **NCT05854784** · PHASE2 · COMPLETED · sponsor: **Clinuvel Pharmaceuticals Limited** · enrollment: 6 (actual)

## Conditions studied

- Variegate Porphyria

## Interventions

- **DRUG:** Afamelanotide 16 MG

## Key facts

- **NCT ID:** NCT05854784
- **Lead sponsor:** Clinuvel Pharmaceuticals Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-28
- **Primary completion:** 2023-12-28
- **Final completion:** 2023-12-28
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05854784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05854784, "Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Variegate Porphyria (VP)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05854784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*